Osemelu Aburime
Ophthalmology · Leesburg, GANPI 1962813303
Payments from drug & device makers
Across 131 payments — averaging $33.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sight Sciences, Inc.$564
- Aerie Pharmaceuticals, Inc.$379
- Sun Pharmaceutical Industries Inc.$223
- Glaukos Corporation$183
- Alcon$160
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,32999%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $1,484 |
| Sight Sciences, Inc. | 16 | $564 |
| Aerie Pharmaceuticals, Inc. | 7 | $379 |
| Sun Pharmaceutical Industries Inc. | 12 | $223 |
| Glaukos Corporation | 3 | $183 |
| Alcon | 10 | $160 |
| Iridex Corporation | 1 | $151 |
| NEW World Medical,inc. | 5 | $146 |
| Boston Scientific | 1 | $146 |
| Eyevance Pharmaceuticals LLC | 1 | $145 |
| Biotissue Holdings Inc. | 3 | $142 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $121 |
| Ocular Therapeutix, Inc. | 3 | $115 |
| Akorn Operating Company LLC | 3 | $97 |
| Tarsus Pharmaceuticals, Inc. | 2 | $58 |
| Bausch & Lomb Americas Inc. | 3 | $56 |
| Amgen(2 entities) | 2 | $41 |
| Merz Pharmaceuticals, LLC | 2 | $40 |
| Novartis | 2 | $36 |
| Harrow Eye, LLC | 1 | $26 |
| Alimera Sciences, Inc. | 1 | $25 |
| Abbott | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$361
- Rocklatan$344
- EXALT Model D$146
- CE-marked KXLA system$145
- Flarex$145
- XEN$125
- LUMIGAN$120
- COMBIGAN$120
- XEN GLAUCOMA TREATMENT SYSTEM$118
- Prokera$113
- AmnioGraft$113
- Rhopressa$101
How this compares
$4,374 in reported general payments places this provider in the 65th percentile of 481 ophthalmology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 291 | $139,267 |
| CombiganBrimonidine Tartrate/Timolol | 120 | $43,761 |
| RhopressaNetarsudil Mesylate | 87 | $37,577 |
| RocklatanNetarsudil Mesylat/Latanoprost | 62 | $29,507 |
| VyzultaLatanoprostene Bunod | 42 | $15,262 |
| RestasisCyclosporine | 11 | $13,536 |
| Alphagan PBrimonidine Tartrate | 28 | $10,832 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 44 | $10,109 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 61 | $7,243 |
| Prednisolone Acetate | 148 | $5,775 |
| Latanoprost | 529 | $5,223 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 135 | $2,115 |
| Travoprost | 20 | $1,961 |
| Brimonidine Tartrate | 114 | $1,827 |
| Dorzolamide Hcl | 81 | $1,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,484 | $207,396450 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $379 | $67,084149 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $56 | $15,26242 claims |
| AlconSimbrinza | $160 | $10,10944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Leesburg
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.